Moderna's 556% Rally Meets a $45 Wall Street Reality Check
Published on 09/26/2026 at 19:41 | Editorial boerse-global.de
Moderna's leadership took the stage at Bernstein's healthcare forum on Wednesday with a familiar message: the company is an mRNA platform play first and foremost, and oncology sits at the heart of its long-term growth story. CEO Stéphane Bancel and development chief David Berman used the "Bernstein Insights: Healthcare Leaders and Disruptors" event to press that case, casting cancer therapeutics as the field that will define the biotech's next chapter.
The host's response came swiftly — and it was anything but a vote of confidence.
Bernstein Holds the Line at $45
A day after the forum, Bernstein reiterated its "Market Perform" rating and kept its price target at just $45.00, drawing that conclusion explicitly from what it heard at its own conference. The signal is hard to miss: even after hearing the management team make its pitch in person, the analysts saw no reason to soften their cautious stance.
That leaves an extraordinary gap on the table. Moderna shares closed Friday's session at €174.30, putting Bernstein's target far below the current market price. Since the start of the year, the stock has climbed 556%, and investors appear eager to price in every ounce of future promise — while fundamental observers warn of overheating.
Should investors sell immediately? Or is it worth buying Moderna?
Bridging that divide with platform rhetoric alone is getting harder. The market wants hard evidence that the technology translates into a profitable business.
All Eyes on October 24
Those sky-high expectations rest largely on the oncology bet. Roughly two weeks ago, Moderna announced Phase 3 data for Intismeran Autogene in resected melanoma stages IIB through IV, a development that sparked euphoria. The results from the program, developed in partnership with Merck's Keytruda, were selected for a Presidential Symposium at the European Society for Medical Oncology (ESMO) congress. Media reports indicate three scientific contributions on the drug candidate were chosen for the upcoming meeting.
October 24, 2026 is the date circled on every calendar. That day brings both the presentation of the late-stage study results and a dedicated investor webcast. The Phase 3 INTerpath-001 trial is testing the personalized cancer vaccine in combination with Keytruda in melanoma patients, and anticipation is likely to build steadily in the meantime.
A Precarious Setup Near Record Highs
The current constellation carries meaningful risk. With the stock trading near its record high of €177.12 — Friday's close left it just 1.6% below that 52-week peak — even a minor disappointment on clinical endpoints could trigger a sharp correction. Ahead of the full study details, the risk-reward balance hardly favors a carefree entry.
Market participants are treating progress in oncology as the decisive yardstick for valuing the entire platform. The pivot toward cancer research gives Moderna a different development profile, one built on long-term clinical value rather than near-term revenue. Whether the combination therapy holds up under scrutiny in real-world clinical practice will only become clear once the late-stage data are dissected.
The platform narrative has carried the valuation a long way. On October 24, it has to deliver.
Ad
Moderna Stock: New Analysis - 26 September
Fresh Moderna information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
